drugset / Trial / NCT00313534
Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
Phase 1
Terminated
15 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.
Timeline
- Start
- 2005-06
- Primary completion
- 2006-10
- Completion
- 2006-10
Outcome
Outcome not reported
Stopped: “Ran out of drug”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | masoprocol | Small molecule | — | Oral |